Replying to:
Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children with relapsed/refractory solid tumors.
Vo KT, Karski EE, Nasholm NM, Allen S, Hollinger F, Gustafson WC, Long-Boyle JR, Shiboski S, Matthay KK, and DuBois SG1 from the Department of Pediatrics, UCSF Benioff Children’s Hospital, University of California, San Francisco School of Medicine, San Francisco, CA; the Department of Clinical Pharmacy, UCSF Benioff Children’s Hospital, University of California, San Francisco School of Medicine, San Francisco, CA, and the Department of Epidemiology and Biostatistics, UCSF Benioff Children’s (...)
